Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size

References

• Hernandez-PastorLJOrtegaAGarcia-LayanaAGiraldezJRanibizumab for neovascular age-related macular degenerationAm J Health Syst Pharm200865191805181418796421
   PubMed Web of Science ®Google Scholar
• MorrisBImrieFArmbrechtAMDhillonBAge-related macular degeneration and recent developments: new hope for old eyes?Postgrad Med J20078397930130717488857
   PubMed Web of Science ®Google Scholar
• RosenfeldPJBrownDMHeierJSMARINA Study GroupRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
   PubMed Web of Science ®Google Scholar
• BrownDMMichelsMKaiserPKHeierJSSyJPIanchulevTANCHOR Study GroupRanibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR studyOphthalmology20091161576519118696
   PubMed Web of Science ®Google Scholar
• MitchellPKorobelnikJFLanzettaPRanibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trialsBr J Ophthalmol201094121319443462
   PubMed Web of Science ®Google Scholar
• GonzalesCRVEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupEnhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysisRetina200525781582716205558
   PubMed Web of Science ®Google Scholar
• RosenfeldPJShapiroHTuomiLWebsterMElledgeJBlodiBMARINA and ANCHOR Study GroupsCharacteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trialsOphthalmology2011118352353020920825
   PubMed Web of Science ®Google Scholar
• MarianiADeliAAmbresinAMantelICharacteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degenerationGraefes Arch Clin Exp Ophthalmol2011249111635164221725716
   PubMed Web of Science ®Google Scholar
• Englund-JohanssonUMohlinCLiljekvist-SolticIEkströmPJohanssonKHuman neural progenitor cells promote photoreceptor survival in retinal explantsExp Eye Res201090229229919931247
   PubMed Web of Science ®Google Scholar
• GerberHPMcMurtreyAKowalskiJVascular endothelial growth factor regulates endothelial cell survival through the phosphati-dylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activationJ Biol Chem19982734630336303439804796
   PubMed Web of Science ®Google Scholar
• FordKMSaint-GeniezMWalsheTZahrAD’AmorePAExpression and role of VEGF in the adult retinal pigment epitheliumInvest Ophthalmol Vis Sci201152139478948722058334
   PubMed Web of Science ®Google Scholar
• ByeonSHLeeSCChoiSHVascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/AktInvest Ophthalmol Vis Sci201051121190119719834034
   PubMed Web of Science ®Google Scholar
• FungAELalwaniGARosenfeldPJAn optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degenerationAm J Ophthalmol2007143456658317386270
   PubMed Web of Science ®Google Scholar
• LalwaniGARosenfeldPJFungAEA variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO StudyAm J Ophthalmol20091481435819376495
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthUMRichardGAugustinAEuropean Society for Retina Specialists’ Guidelines Committee (EURETINA): Guidance for the treatment of neovascular age-related macular degenerationActa Ophthalmol Scand200785548649417655610
   PubMedGoogle Scholar
• IpMSScottIUBrownGCAnti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of OphthalmologyOphthalmology2008115101837184618929163
   PubMed Web of Science ®Google Scholar
• MekjavicPJKrautAUrbancicMLenassiEHawlinaMEfficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injectionsActa Ophthalmol201189764765319860774
   PubMed Web of Science ®Google Scholar
• RosinaCBottoniFStaurenghiGClinical experience with pegaptanib sodiumClin Ophthalmol20082348548819668746
   PubMedGoogle Scholar
• MaderJSSmythDMarshallJHoskinDWBovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cellsAm J Pathol200616951753176617071598
   PubMed Web of Science ®Google Scholar
• VinoresSAPegaptanib in the treatment of wet, age-related macular degenerationInt J Nanomedicine20061326326817717967
   PubMed Web of Science ®Google Scholar
• Van de VeireSVan BergenTVandewalleECarmelietPMoonsLStalmansIThe role of the VEGF-isoforms in pathological choroidal/ retinal angiogenesisBull Soc Belge Ophtalmol20113175521560860
   PubMedGoogle Scholar
• ManoonkitiwongsaPSCritical questions for preclinical trials on safety and efficacy of vascular endothelial growth factor-based therapeutic angiogenesis for ischemic strokeCNS Neurol Disord Drug Targets201110221523420874695
   PubMed Web of Science ®Google Scholar
• KimIRyanAMRohanRConstitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyesInvest Ophthalmol Vis Sci19994092115212110440268
   PubMed Web of Science ®Google Scholar
• FribergTRTolentinoMWeberPPatelSCampbellSGoldbaumMLEVEL Study GroupPegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL studyBr J Ophthalmol201094121611161720472746
   PubMed Web of Science ®Google Scholar
• RicciFMissiroliFCedroneCGrossiMRegineFCompassionate use of intravitreal pegaptanib in patients with age-related macular degenerationSemin Ophthalmol2010251–2162020507192
   PubMed Web of Science ®Google Scholar
• WeberPAWirostkoBMXuXGossTFZlatevaGNewly diagnosed exudative age-related macular degeneration treated with pegaptanib sodium monotherapy in US community-based practices: medical chart review studyBMC Ophthalmol201010220144224
   PubMed Web of Science ®Google Scholar
• BhisitkulRBVascular endothelial growth factor biology: clinical implications for ocular treatmentsBr J Ophthalmol200690121542154717114590
   PubMed Web of Science ®Google Scholar
• RakicJMLambertVDevyLPlacental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularizationInvest Ophthalmol Vis Sci20034473186319312824270
   PubMed Web of Science ®Google Scholar